Crown Bioscience has announced that they will merge with and become a fully owned subsidiary of the JSR Corporation, headquartered in Tokyo, Japan. The merger, which cost JSR $400 million, produces a fully integrated suite of innovative solutions to support researchers through every stage of drug and diagnostic development – from early research through manufacturing. The strategic merger integrates Crown Bioscience’s translational technology platform with JSR’s in vitro diagnostic (IVD) solu...